Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Join ASFA
Partner Resources

 Partner Resources

 

FACT - ASFA Allied Learning Center


FACT has created an Allied Learning Center that provides a centralized resource for organizations to quickly and easily obtain online modules applicable to their operations and/or training needs from all organizations affiliated with the cellular therapy community. FACT encourages accredited organizations to utilize these educational activities to maintain knowledge of industry practices and regulations.

http://www.factwebsite.org/alliedlearningcenter/

 


Therapeutic Plasma Exchange (TPE) and Intravenous Immunoglobulin (IVIG)



Refer to the following article that addresses a cost minimization analysis of the direct costs of TPE and IVIG treatments.

http://www.biomedcentral.com/1472-6963/11/101

Given equivalent efficacy and similar severity and frequencies of adverse events, TPE appears to be a less expensive first-line therapy option. For additional information regarding the cost model addressed in this article please contact Claudia Cobianchi at claudia.cobianchi@terumobct.com.

 


Growing Your TPE/PLEX Business – The Value Proposition


Download and watch this free presentation today! This resource is a live recording of a presentation delivered by Ashok Chainani of CardianBCT demonstrating best practices and offering free resources for growing your TPE/PLEX business.



Title: Growing Your TPE/PLEX Business – The Value Proposition
Presenter: Ashok Chainani, CaridianBCT
Presentation Objectives:

  1. Learn about cost differences between two different treatment regimens – Therapeutic Plasma Exchange (TPE/PLEX) and IVIG.
  2. Leverage the knowledge to inform physicians of the TPE/PLEX option.
  3. Key take-away: In the outpatient setting, TPE/PLEX offers significant savings while providing comparable¹ health outcomes.

Source: ¹ Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230. to download this presentation now. Please note you will need quicktime or iTunes to view this file


Click Here to Download this Presentation Now. (Please note: This file is in MP4 format and you will need Quicktime or iTunes to view this presentation)

    

Circular Information for the Use of Cellular Therapy Products


This circular was prepared jointly by the AABB, America’s Blood Centers, the American Association of Tissue Banks, the American Red Cross, the American Society for Apheresis, the American Society for Blood and Marrow Transplantation, the College of American Pathologists, the Cord Blood Association, the Foundation for the Accreditation of Cellular Therapy, ICCBBA, the International Society for Cellular Therapy, the Joint Accreditation Committee of ISCT and EBMT, the National Marrow Donor Program, and Netcord. Federal law prohibits dispensing the cellular therapy products described in this circular without a prescription. 

Click Here to access the full document.